Adverse events related to dalbavancin and linezolid therapy to treat skin infections

  • Lilián María
Keywords: Skin infections, dalbavancin and linezolid therapy, Clinical and microbiological evaluations

Abstract

Dalbavancin is a novel, semisynthetic lipoglycopeptide antibacterial with a pharmacokinetic profile that allows weekly dosing. It has potent in vitro activity against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus, and it is superior to most of the other antibiotics used to treat gram-positive bacterial infections, including vancomycin.

Published
2020-03-01